Discovering novel direct acting antiviral agents for HBV using in silico screening

Murakami, Y. Hayakawa, M. Yano, Y. Tanahashi, T. Enomoto, M. Tamori, A. Kawada, N. Iwadate, M. Umeyama, H.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):20-8.

Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice

Ishida Y, Yamasaki C, Yanagi A, Yoshizane Y, Fujikawa K, Watashi K, Abe H, Wakita T, Hayes CN, Chayama K, Tateno C

Am J Pathol. 2015 May;185(5):1275-85. doi: 10.1016/j.ajpath.2015.01.028. Epub 2015 Mar 17.

Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection

Hamada-Tsutsumi, S. Iio, E. Watanabe, T. Murakami, S. Isogawa, M. Iijima, S. Inoue, T. Matsunami, K. Tajiri, K. Ozawa, T. Kishi, H. Muraguchi, A. Joh, T. Tanaka, Y.

PLoS One. 2015 Feb 18;10(2):e0118062.

Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)

Watashi, K. Sluder, A. Daito, T. Matsunaga, S. Ryo, A. Nagamori, S. wamoto, M. Nakajima, S. Tsukuda, S. Borroto-Esoda, K. Sugiyama, M. Tanaka, Y. Kanai, Y. Kusuhara, H. Mizokami, M. Wakita, T.

Hepatology. 2014 May;59(5):1726-37.

In vitro evaluation of cytochrome p450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice.

Yamasaki C, Kataoka M, Kato Y, Kakuni M, Usuda S, Ohzone Y, Matsuda S, Adachi Y, Ninomiya S, Itamoto T, Asahara T, Yoshizato K, Tateno C.
Drug Metab Pharmacokinet. 2011 Jan 14;25(6):539-50